Unexpectedly long half-life of metformin elimination in cases of metformin accumulation

Diabetic Medicine

Volumn 33, Issue 1, 2016, Pages 105-110

  Kajbaf, F ^a,b   Bennis, Y ^a   Hurtel Lemaire, A S ^a   Andrejak M ^a   Lalau, J D ^a,b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ARTICLE; BLOOD SAMPLING; DIALYSIS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; ELIMINATION HALF-LIFE; ERYTHROCYTE; HOSPITAL ADMISSION; HUMAN; LACTIC ACIDOSIS; SYSTEMATIC REVIEW; ACIDOSIS, LACTIC; ACUTE KIDNEY INJURY; AGED; ALGORITHM; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HALF LIFE TIME; HEMODIALYSIS; MALE; MEDICAL RECORD; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TISSUE DISTRIBUTION; URINARY EXCRETION;

ACIDOSIS, LACTIC; ACUTE KIDNEY INJURY; AGED; ALGORITHMS; BLOOD; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ERYTHROCYTES; FEMALE; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICAL RECORDS; METFORMIN; MIDDLE AGED; RENAL DIALYSIS; RENAL ELIMINATION; SEVERITY OF ILLNESS INDEX; TISSUE DISTRIBUTION;

EID: 84955749139     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12959     Document Type: Article

References (14)

1. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011; 50: 81-98.
2. Robert F, Fendri S, Hary L, Lacroix C, Andréjak M, Lalau JD. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. Diabetes Metab 2003; 29: 279-283.
3. Lalau JD, Lacroix C. Measurement of metformin concentration in erythrocytes: clinical implications. Diabetes Obes Metab 2003; 5: 93-98.
4. Lalau JD, Kajbaf F. Interpreting the consequences of metformin accumulation in an emergency context: impact of the time frame on the blood metformin levels. Int J Endocrinol 2014; Article ID 717198, doi:10.1155/2014/717198.
5. FDA label approved on 07/19/2013 (PDF) for Metformin Hydrochloride, ANDA no. 091664. Available at www.accessdata.fda.gov/drugsatfda_docs/label/2013/091664Orig1s000lbl.pdf Last accessed 21 April 2015.
6. Lacroix C, Danger P, Wojciechowski F. Microassay of plasma and erythrocyte metformin by high performance liquid chromatography. Ann Biol Clin (Paris) 1991; 2: 98-101.
7. Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf 2010; 33: 727-740.
8. Lalau JD, Lacroix C, Compagnon P, de Cagny B, Rigaud JP, Bleichner G et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995; 18: 779-784.
9. Lalau JD, Andrejak M, Morinière P, Coevoet B, Debussche X, Westeel PF et al. Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol 1989; 27: 285-288.
10. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994; 24: 49-57.
11. Todd JN, Florez JC. An update on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics 2014; 15: 529-539.
12. Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. Metformin pharmacogenomics: current status and future directions. Diabetes 2014; 63: 2590-2599.
13. Chen S, Zhou J, Xi M, Jia Y, Wong Y, Zhao J et al. Pharmacogenetic variation and metformin response. Curr Drug Metab 2013; 14: 1070-1082.
14. 1c. Pharmacogenet Genomics 2011; 21: 837-850.